Asenapine
Alternative Names: Asenapine maleate; Atisenap; ME2136; ORG-5222; Saphris; SCH-900274; SycrestLatest Information Update: 05 Nov 2023
At a glance
- Originator Organon
- Developer AbbVie; Lundbeck A/S; Meiji Seika Pharma; Merck & Co
- Class Antipsychotics; Heterocyclic compounds with 4 or more rings; Oxepins; Pyridines; Pyrrolidines; Small molecules
- Mechanism of Action Alpha adrenergic receptor antagonists; Dopamine receptor antagonists; Histamine H1 receptor antagonists; Serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bipolar disorders; Schizophrenia
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 20 Jul 2017 Merck terminates a phase II trial as the funding ended due to recruitment delays for Bipolar disorders in USA (PO) (NCT01807741)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia(In children) in USA (Sublingual, Tablet)